Skip to main content
Erschienen in: Pituitary 3/2017

24.03.2017

Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas

verfasst von: Mark Gruppetta, Robert Formosa, Sharon Falzon, Sabrina Ariff Scicluna, Edward Falzon, James Degeatano, Josanne Vassallo

Erschienen in: Pituitary | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The pathogenesis of pituitary adenomas (PA) is complex. Ki-67, pituitary tumour transforming gene (PTTG), vascular endothelial growth factor (VEGF), cyclin D1, c-MYC and pituitary adenylate cyclase-activating peptide (PACAP) protein expression were analysed and correlated with tumour and patient characteristics.

Methods

74 pituitary tumour samples (48 non-functional PA, 26 functional PAs); Immunohistochemical analysis of protein expression, retrospective analysis of MR images and in vitro analysis of octreotide treatment was carried out on GH3 cells.

Results

PTTG expression was negatively associated with age and positively with PA size, regrowth and Ki-67 index. Cyclin D1 correlated with Ki-67 and tumour size. c-MYC negatively correlated with size of tumour and age; and correlated with PTTG expression. Somatostatin analogue treatment was associated with lower Ki-67, PTTG and Cyclin D1 expression while T2 hypointense PAs were associated with lower PTTG, cyclin D1, c-MYC and Ki-67. In vitro analyses confirmed the effect of somatostatin analogue treatment on Pttg and Cyclin D1 expression.

Conclusions

Interesting and novel observations on the differences in expression of tumour markers studied are reported. Correlation between Ki-67 expression, PTTG nuclear expression and recurrence/regrowth of PAs, emphasizes the role that Ki-67 and PTTG expression have as markers of increased proliferation. c-MYC and PTTG nuclear expression levels were correlated providing evidence that PTTG induces c-MYC expression in PAs and we propose that c-MYC might principally have a role in early pituitary tumorigenesis. Evidence is shown that the anti-proliferative effect of somatostatin analogue treatment in vivo occurs through regulation of the cell cycle.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321CrossRefPubMed Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321CrossRefPubMed
3.
Zurück zum Zitat Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65:536–543CrossRef Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65:536–543CrossRef
4.
Zurück zum Zitat McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJL (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol 58:141–150CrossRef McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJL (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol 58:141–150CrossRef
5.
Zurück zum Zitat Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMed Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMed
6.
Zurück zum Zitat Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269–324PubMed Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269–324PubMed
7.
Zurück zum Zitat Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16(4):545–553CrossRefPubMed Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16(4):545–553CrossRefPubMed
8.
Zurück zum Zitat Gruppetta M, Vassallo J (2016) Epidemiology and radiological geometric assessment of pituitary macroadenomas: population based study. Clin Endocrinol 85:223–231CrossRef Gruppetta M, Vassallo J (2016) Epidemiology and radiological geometric assessment of pituitary macroadenomas: population based study. Clin Endocrinol 85:223–231CrossRef
9.
Zurück zum Zitat Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82(3):818–824PubMed Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82(3):818–824PubMed
10.
Zurück zum Zitat Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–618CrossRefPubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–618CrossRefPubMed
11.
Zurück zum Zitat Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766CrossRefPubMed Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766CrossRefPubMed
12.
Zurück zum Zitat Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679CrossRefPubMed Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679CrossRefPubMed
13.
Zurück zum Zitat Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751CrossRefPubMed Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751CrossRefPubMed
14.
Zurück zum Zitat Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406–4413CrossRefPubMed Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406–4413CrossRefPubMed
15.
Zurück zum Zitat Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106CrossRefPubMed Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106CrossRefPubMed
16.
Zurück zum Zitat Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore, G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113CrossRefPubMed Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore, G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113CrossRefPubMed
17.
Zurück zum Zitat Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY (2006) PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 17:143–153CrossRefPubMed Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY (2006) PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 17:143–153CrossRefPubMed
18.
Zurück zum Zitat Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA (1999) Hpttg is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18:5473–5476CrossRefPubMed Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA (1999) Hpttg is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18:5473–5476CrossRefPubMed
19.
Zurück zum Zitat Bradshaw C, Kakar SS (2007) Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol 22(2):219–226PubMed Bradshaw C, Kakar SS (2007) Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol 22(2):219–226PubMed
20.
Zurück zum Zitat Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP (2005) Securin is overexpressed in breast cancer. Mod Pathol 18(7):985–990CrossRefPubMed Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP (2005) Securin is overexpressed in breast cancer. Mod Pathol 18(7):985–990CrossRefPubMed
21.
22.
Zurück zum Zitat Prochownik EV (2008) c-Myc: linking transformation and genomic instability. Curr Mol Med 8(6):446–458CrossRefPubMed Prochownik EV (2008) c-Myc: linking transformation and genomic instability. Curr Mol Med 8(6):446–458CrossRefPubMed
23.
Zurück zum Zitat Pei L (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276:8484–8491CrossRefPubMed Pei L (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276:8484–8491CrossRefPubMed
24.
Zurück zum Zitat Formosa R, Gruppetta M, Falzon S, Santillo G, DeGaetano J, Xuereb-Anastasi A, Vassallo J (2012) Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol 23(2):123–131CrossRefPubMed Formosa R, Gruppetta M, Falzon S, Santillo G, DeGaetano J, Xuereb-Anastasi A, Vassallo J (2012) Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol 23(2):123–131CrossRefPubMed
25.
Zurück zum Zitat Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145:5439–6477CrossRefPubMed Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145:5439–6477CrossRefPubMed
26.
Zurück zum Zitat Diehl JA, Zindy F, Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Gene Dev 11(8):957–972CrossRefPubMed Diehl JA, Zindy F, Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Gene Dev 11(8):957–972CrossRefPubMed
27.
Zurück zum Zitat Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG, McDonald KL (2008) Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149:1235–1242CrossRefPubMed Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG, McDonald KL (2008) Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149:1235–1242CrossRefPubMed
28.
Zurück zum Zitat Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143:R1–R6CrossRefPubMed Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143:R1–R6CrossRefPubMed
29.
Zurück zum Zitat Oka H, Jin L, Reubi JC, Qian X, Scheithauer BW, Fujii K, Kameya T, Lloyd RV (1998) Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. American J Pathol 153(6):1787–1796CrossRef Oka H, Jin L, Reubi JC, Qian X, Scheithauer BW, Fujii K, Kameya T, Lloyd RV (1998) Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. American J Pathol 153(6):1787–1796CrossRef
30.
Zurück zum Zitat McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244CrossRefPubMed McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244CrossRefPubMed
31.
Zurück zum Zitat Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D (2010) VEGF and CD31 association in pituitary adenomas. Endocr Pathol 21:154–160CrossRefPubMed Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D (2010) VEGF and CD31 association in pituitary adenomas. Endocr Pathol 21:154–160CrossRefPubMed
32.
Zurück zum Zitat Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E, Renner U (2012) RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr Relat Cancer 19(1):13–27CrossRefPubMed Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E, Renner U (2012) RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr Relat Cancer 19(1):13–27CrossRefPubMed
33.
Zurück zum Zitat Sánchez-Ortiga R, Sánchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, Picó Alfonso AM (2013) Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16:370–377CrossRefPubMed Sánchez-Ortiga R, Sánchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, Picó Alfonso AM (2013) Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary 16:370–377CrossRefPubMed
34.
Zurück zum Zitat Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JAH, Harris AL (2000) Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumor behaviour. Br J Cancer 82:1441–1445CrossRefPubMedPubMedCentral Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JAH, Harris AL (2000) Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumor behaviour. Br J Cancer 82:1441–1445CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC (2006) Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9(1):27–34CrossRefPubMed Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC (2006) Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9(1):27–34CrossRefPubMed
36.
Zurück zum Zitat Cap J, Cerman J, Nemecek S, Marekova M, Hana V, Frysak Z (2003) The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 10:444–448CrossRefPubMed Cap J, Cerman J, Nemecek S, Marekova M, Hana V, Frysak Z (2003) The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci 10:444–448CrossRefPubMed
37.
Zurück zum Zitat Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Cavnanni F, Giovanelli M (2001) Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194–5200CrossRefPubMed Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Cavnanni F, Giovanelli M (2001) Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 86:5194–5200CrossRefPubMed
38.
Zurück zum Zitat Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538CrossRefPubMed Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538CrossRefPubMed
39.
Zurück zum Zitat Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100(1):122–131CrossRefPubMed Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100(1):122–131CrossRefPubMed
40.
Zurück zum Zitat Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499CrossRefPubMed Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499CrossRefPubMed
Metadaten
Titel
Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas
verfasst von
Mark Gruppetta
Robert Formosa
Sharon Falzon
Sabrina Ariff Scicluna
Edward Falzon
James Degeatano
Josanne Vassallo
Publikationsdatum
24.03.2017
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2017
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0803-0

Weitere Artikel der Ausgabe 3/2017

Pituitary 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.